The drug commonly used for hormonal treatment in mares is now being tracked by the USEF. Get the information you’ll need to stay on the up and up right here.
PC: Phil King/cc/flickr
Lexington, Ky. – US Equestrian (USEF) announced today that September 1, 2017 will serve as the effective start date for disclosure and reporting of horses that are being given medroxyprogesterone acetate (MPA), commonly known as the human product Depo-Provera®. This is a follow-up to the announcement following US Equestrian’s Mid-Year Meeting and the Board of Director’s approval of the recommendation of the USEF MPA Panel.
The use of MPA is currently allowed at US Equestrian licensed competitions. In an effort to better understand the use of MPA in horses competing at US Equestrian licensed competitions, the collection of MPA disclosure forms will allow for a gathering of pharmacokinetic data in relation to the administration of MPA, including how long it lasts in horses’ systems.
If a horse has received MPA and is competing at a USEF licensed competition on September 1 or thereafter, an MPA Disclosure Form must be completed. Horses given MPA 90 days or less prior to September 1, who are competing on September 1, must also have a completed form.
Exhibitors will be able to locate the MPA Disclosure Form on the US Equestrian website, in both an electronic, as well as print version of the form. Additionally, an MPA Disclosure Form FAQ can be found online to assist with additional inquiries and questions.
It should be noted that an MPA Disclosure Form does not replace a Medication Report Form (MRF). An MRF should be filled out separately for all other medications, according to USEF Drugs and Medications rules and regulations.